🇺🇸 Insulin glargine (LANTUS) in United States

39 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Hyperglycaemia — 7 reports (17.95%)
  2. Dyspnoea — 5 reports (12.82%)
  3. Asthenia — 4 reports (10.26%)
  4. Dehydration — 4 reports (10.26%)
  5. Hypotension — 4 reports (10.26%)
  6. Diabetic Ketoacidosis — 3 reports (7.69%)
  7. Drug Ineffective — 3 reports (7.69%)
  8. Gastrointestinal Haemorrhage — 3 reports (7.69%)
  9. Mental Status Changes — 3 reports (7.69%)
  10. Pneumonia — 3 reports (7.69%)

Source database →

Other Diabetes approved in United States

Frequently asked questions

Is Insulin glargine (LANTUS) approved in United States?

Insulin glargine (LANTUS) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Insulin glargine (LANTUS) in United States?

Sanofi is the originator. The local marketing authorisation holder may differ — check the official source linked above.